资讯

Clinical Trials Arena on MSN7 天
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...
Fierce Pharma8 天
AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial
Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...
MyChesCo on MSN15 小时
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer
Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...
PharmiWeb8 天
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety ...
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...
The Pharma Letter8 天
AstraZeneca and Daiichi push Enhertu into earlier breast cancer use
UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...
Yahoo Finance7 天
AstraZeneca, Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
Clinical Trials Arena · Jo Panuwat D/Shutterstock. AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), followed by paclitaxel, trastuzumab and pertuzumab (THP), has shown ...
Seeking Alpha8 天
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...